Section 19D1/2: Substance use disorder treatment facility; dispense of opioid antagonist to patient or a legal guardian; promulgation of regulations
[ Text of section added by 2024, 285, Sec. 5 effective July 1, 2025. See 2024, 285, Sec. 48.]
Section 19D1/2. (a) For the purposes of this section, the following words shall, unless the context clearly requires otherwise, have the following meanings:
"Opioid antagonist'', as defined in section 19B.
"Substance use disorder treatment facility'', a facility licensed or approved by the department or the department of mental health to offer treatment for substance use disorder, including, but not limited to: (i) withdrawal management services; (ii) clinical stabilization services; (iii) transitional support services; (iv) residential support services; (v) community behavioral health center services; (vi) office-based opioid or addiction treatment services; or (vii) inpatient or outpatient substance use disorder services.
(b) A substance use disorder treatment facility shall, upon discharge of a patient who has: (i) a history of using opioids; (ii) been diagnosed with opioid use disorder; or (iii) experienced an opioid-related overdose, educate the patient on the use of opioid antagonists and dispense not less than 2 doses of an opioid antagonist to the patient or a legal guardian.
(c) The commissioner may promulgate rules and regulations necessary to implement this section.